Maia Kayal, MD

Anita Afzali, MD, discusses treatment approaches to ulcerative colitis (UC) and how they may differ from Crohn’s Disease (CD).

Experts summarize their clinical strategies for monitoring and treating patients with Crohn’s Disease (CD).

Millie Long, Miguel Regueiro, MD, Maia Kayal, MD, Anita Afzali, MD, and David Hudesman, MD, offer clinical strategies for optimizing treatments for Crohn’s Disease (CD) patients.

Miguel Regueiro, MD, offers his clinical advice on second-line therapies for patients with Crohn’s Disease (CD).

Anita Afzali, MD, David Hudesman, MD, and Maia Kayal, MD, discuss how extra intestinal manifestations (EIM) affect therapy strategies for Crohn’s Disease (CD) patients.

Millie Long discusses treatment considerations for Crohn’s Disease (CD) patients who are planning for pregnancy.

Experts discuss the results of a five-year efficacy and safety trial of ustekinumab for treatment of Crohn’s Disease (CD).

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).

Drs. Maia Kayal and David P. Hudesman discuss their hopes and future directions in the treatment of patients with ulcerative colitis.

Experts in gastroenterology share the clinical trial end points and metrics they use to guide their treatment of patients with ulcerative colitis.

Maia Kayal, MD, explains how treatment guidelines can be used to direct and standardize treatment approaches in patients with ulcerative colitis.

Maia Kayal, MD, and David P. Hudesman, MD, discuss the importance of efficacy and safety data in the management of patients with ulcerative colitis and how this impacts treatment choice.

Experts in gastroenterology provide an overview of induction vs maintenance therapy options, and comment on how their approach to treatment differs in patients with disease remission.

Maia Kayal, MD, and David P. Hudesman, MD, review their approaches to treatment in patients with ulcerative colitis.

Drs Maia Kayal and David P. Hudesman provide an overview of the treatment landscape for the management of ulcerative colitis, highlighting efficacy and safety considerations.

An expert in gastroenterology shares her opinion on the current unmet needs and treatment challenges for patients with ulcerative colitis.

David P. Hudesman, MD, explains the differences between active and inactive disease and discusses the role of early ulcerative colitis detection in the optimization of patient care.

Maia Kayal, MD, and David P. Hudesman, MD, highlight the burden of disease and comment on the impact ulcerative colitis has on a patient’s quality of life.

Maia Kayal, MD, provides and overview of ulcerative colitis, highlighting symptomology, comorbidities, and the disease impact on patient’s quality of life.